Reports Q1 revenue $71.7M, consensus $64.15M. Joseph Capper, CEO, commented, "Our first quarter 2023 results demonstrate an excellent level of focus and execution across our organization, particularly among our commercial team. Our double-digit net sales growth this quarter was driven by robust demand for our new products in the surgical market and an accelerated growth rate in the private physician office setting. Our entire product offering is winning across the care settings we serve, as we work to make our best-in-class placental biologics products available to a large and growing number of patients each day."
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDXG:
- MIMEDX Announces First Quarter 2023 Operating and Financial Results
- Is MDXG a Buy, Before Earnings?
- MIMEDX to Host First Quarter 2023 Operating and Financial Results Conference Call on May 2
- MiMedx announces CFO Peter Carlson leaving, company initiates search
- MIMEDX Announces Chief Financial Officer Transition